Heron Therapeutics Inc. Announces Leadership Update and Stock Performance Overview

Heron Therapeutics, Inc., a biotechnology company based in San Diego, United States, has recently announced a significant update in its senior leadership team. The company, which operates within the Health Care sector, has appointed Mark Hensley as its new Chief Operating Officer (COO). This strategic move is part of Heron Therapeutics’ ongoing efforts to strengthen its leadership team and drive forward its mission in the biotechnology industry.

Heron Therapeutics is known for its proprietary biochronomer drug delivery technology, which aims to enhance the therapeutic profile of injectable pharmaceuticals. The company also focuses on identifying existing therapies that can be reformulated to improve their efficacy and delivery. These initiatives are central to Heron’s strategy in advancing healthcare solutions.

In terms of financial performance, Heron Therapeutics’ stock has experienced notable fluctuations over the past year. The stock reached a 52-week high of $3.93 USD on June 11, 2024, and a 52-week low of $1.04 USD on November 11, 2024. As of May 4, 2025, the stock price is $2.31 USD, reflecting a $1.29 USD range from its 52-week high. The company’s market capitalization stands at approximately $358.45 million USD, with a price-to-earnings ratio of -26.31, indicating that the company is not currently profitable.

Heron Therapeutics, Inc. was initially public on August 26, 1987, and is listed on the Nasdaq stock exchange. For more detailed information about the company’s activities and developments, interested parties can visit their website at www.herontx.com .

The appointment of Mark Hensley as COO is expected to bolster Heron’s operational capabilities and support its strategic objectives in the biotechnology field. As the company continues to navigate the dynamic healthcare landscape, these leadership changes are anticipated to play a crucial role in its future growth and innovation efforts.